Summary.-Leukaemia cells from the peripheral blood and bone marrow of patients with acute myeloblastic leukaemia were labelled in vitro with [1251] 5 -iodo-2'-deoxyuridine (IUdR). The myeloblasts were then injected into groups of mice and the survival of these cells estimated by measuring isotope loss, using whole-body counting. The isotope excretion from mice treated with various doses of cytosine arabinoside (Ara-C) and those not treated with drugs were compared. This comparison showed that the sensitivity of myeloblasts to the drug varies from patient to patient, and in one case was different for myeloblasts from bone marrow and from blood from the same patient. We compare the clinical responses of myeloblasts to
MEASUREMENT of 1251 release from [12 51]5-iodo-2'-deoxyuridine (IUdR)-labelled cells has been used to assess cell survival in vivo in a number of animal models (Hughes et al., 1964; Porteous and Munro, 1972) . In the previous paper in this series (Falcao et al., 1977) we described a technique for labelling both fresh and cryopreserved human leukaemic myeloblasts with IUdR, and we investigated the fate of the labelled cells after they had been injected into mice. The present study was undertaken to establish, in principle, whether this technique can be used to assess the susceptibility in vivo of human leukaemic myeloblasts to chemotherapy.
PATIENTS
The patients studied had definite acute myelobastic leukaemia. Brief clinical details are given in the legends to figures. We are extremely grateful to Drs C. Bunch, S. Callender, C. Potter and Professor D.
Weatherall for allowing us to study their patients. Five of the patients were treated by low-dose cytosine arabinoside (Ara-C) infusion as part of a pilot study being carried out at Oxford by these workers. The rational basis for this treatment and the reasons for dose selection will be described elsewhere. In Fig. 2A , 200 mg Ara-C/m2.
-400 mg Ara-C/m2. Fit:. 2B. This 72-5kg patient presente(t with a blood myeloblast count of 63 x 109/1. Bone marrowN, aspiration at that time only yielded dark brown necrotic tissue at three sites. He was treated with continuous i.v. infusion of Ara-C 20 mg/day for 2 days and 80 mg/day for 5 days, before his bloodt myeloblast count fell to 1 x 1 O9/I. Bloocd myeloblasts were studied immediately before tieatmenit.
-no diug. have a high spontaneous rate of JUdR release. In each case, about 90% of injected radioactivity is lost within 48 h. This high rate of isotope release is probably due to rapid death of the labelled cells. It is gratifying to see that despite this, a significant cytotoxic effect of Ara-C is demonstrable in mice, against the myeloblasts of the patient depicted in Fig. 3A . Fig. 3B and C indicate that different characteristics may be seen in myeloblasts from a single individual taken from different sites. The marrow myeloblasts from this patient represented in Fig. 3C have a low rate of 125J loss, and these cells appear sensitive to damage by Ara-C. On the other hand the same patient's peripheral blood myeloblasts (Fig. 3B) show more rapid spontaneous release of isotope, and this is not increased further by the administration of Ara-C. We have compared marrow and blood myeloblasts in 2 other patients. In these patients the drug sensitivity and spontaneou srate of isotope release did not differ between cells from the two sites. In all 3 patients the number of counts taken up by marrow cells was greater than that by blood cells. Fig. 4 shows the rate of excretion of 125J from mice injected with IUdR-labelled myeloblasts from 2 further patients. The spontaneous rate of isotope release is not particularly high from the myeloblasts from either patient, but in neither case did Ara-C increase isotope release. The clinical history of the response to Ara-C in these 2 patients, which is given in the legend to Fig. 3 cell death is assessed by 1251 excretion. Such a result is in agreement with earlier studies in which 125J elimination was used to study the response of a murine leukaemia to methotrexate (Hofer et at., 1969; Hofer, 1972) . Evaluation of our results was facilitated by the fact that all the patients studied had relatively high peripheral myeloblast counts at presentation, and that 5/6 patients described were treated only with Ara-C. The use of the thymidine analog, IUdR, to label myeloblasts, means that the label is only incorporated into cells actively synthesizing DNA. The growth fraction of myeloblasts is far from 100% (Crowther et al., 1975) and so in this assay the sensitivity is not being assessed for all leukaemic cells from a patient. However, 21 this theoretical objection is to some extent academic if the assay we describe is shown to correlate consistently with the clinical response to the drugs.
Myeloblasts die, as measured by 1251 excretion, 2-5 days after injection into mice. This interval is sufficient to measure the effect of drugs on myeloblast viability. The relative contribution of host rejection and spontaneous death of myeloblasts to the rate of 125I loss is discussed in some detail in our previous publication in this issue (Falca-o et al., 1977) .
The assay may be of particular value in three contexts: in testing the susceptibility of neoplastic cells to specific agents where multiple drug therapy is contemplated; in the selection of second-line drugs in cases where primary therapy has failed; and finally in the preliminary investigation of new cytotoxic agents and schedules for anti-leukaemic effect.
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